Pharmacy Search
Vertice Login
Menu
close

Medmonitor

An up-to-date timeline of U.S. Food and Drug Administration (FDA) approvals that could potentially impact workers' compensation. These include new drug and indication approvals, new dosages or formulations of existing products, and generics introduced to the market. Click through the interactive timeline below, or select the comprehensive list view.
← Back to Medmonitor

Medication Type: Opioid

Nucynta (tapentadol hydrochloride) tablets

Approval Date: Jan 2026

Note: First-Time Generic

An opioid analgesic indicated for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate in patients weighing at least 40 kg

Nucynta (tapentadol hydrochloride) oral solution

Approval Date: Jan 2026

Note: First-Time Generic

An opioid analgesic indicated for the relief of moderate to severe pain

Dilaudid (hydromorphone hydrochloride) injection

Approval Date: Feb 2024

Note: First-Time Generic

Indicated for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate

Medication Name

Approval Date

Category

Description

Nucynta (tapentadol hydrochloride) tablets

Jan 2026

An opioid analgesic indicated for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate in patients weighing at least 40 kg

Note: First-Time Generic

Nucynta (tapentadol hydrochloride) oral solution

Jan 2026

An opioid analgesic indicated for the relief of moderate to severe pain

Note: First-Time Generic

Dilaudid (hydromorphone hydrochloride) injection

Feb 2024

Indicated for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate

Note: First-Time Generic
lockenvelopephone-handsetmagnifiermenucross-circle